A pharmacy can have strong foot traffic, trusted staff, and a good location – and still underperform in front-of-store sales because the assortment is working against the business. That is why non prescription assortment planning deserves management attention. In most pharmacies, OTC and consumer health sales do not stall because demand disappears. They stall because the mix is too broad, too repetitive, poorly segmented, or disconnected from what local patients actually buy.
For pharmacy owners and managers, assortment planning is not a shelf-filling exercise. It is a commercial decision that affects cash flow, category productivity, patient experience, and the credibility of the pharmacy team. The right assortment supports recommendation-based selling and makes the store easier to shop. The wrong one creates clutter, slows decisions, ties up capital, and leaves good products invisible.
What non prescription assortment planning really means
Non prescription assortment planning is the structured process of deciding which OTC, wellness, self-care, and adjacent front-of-store products should be stocked, in what breadth, at what depth, and with what role inside the pharmacy. It is both a merchandising task and a strategic management discipline.
That distinction matters. Many pharmacies add products reactively – because a supplier promoted a line, a competitor listed it, or a sales representative made a persuasive case. Over time, this produces duplication across brands, weak turnover in secondary SKUs, and categories that occupy more space than their commercial contribution justifies.
A planned assortment starts from a different question: what should this pharmacy be known for, and which products support that position profitably and credibly?
For one store, that may mean leadership in cold and flu, digestive care, pain relief, and family health. For another, it may mean stronger development in dermocosmetics, prevention, and healthy aging. Both can be valid. The important point is that the assortment should express a strategy, not just reflect supplier pressure.
Why pharmacies struggle with assortment decisions
The most common problem is range inflation. A category that could perform with 20 well-chosen SKUs ends up carrying 38. The result is not necessarily more sales. Often, it is slower stock rotation, more dead inventory, and less visual clarity for the customer.
A second issue is treating all categories equally. They are not equal. Some categories are traffic drivers, some are margin generators, some strengthen the healthcare role of the pharmacy, and some mainly exist to complete the offer. If management does not define those roles, shelf space tends to be distributed by habit.
The third issue is weak use of data. Pharmacies often know which products are popular in general terms, but not which subcategories are overstocked, which brands are carrying too many low-volume variants, or which items consume shelf space without delivering enough gross profit.
This is where a more disciplined approach helps. Pharmacy management & COMMUNICATION has long emphasized that commercial performance in pharmacy improves when operational choices are treated as strategic decisions. Assortment is one of the clearest examples.
Start with category roles, not brands
A productive non prescription assortment planning process begins at category level. Before deciding which brand or pack size stays, define what each category is expected to do.
Pain relief, cough and cold, allergy, digestive support, first aid, and oral care often carry a core role in many pharmacies because they answer frequent, immediate needs. Categories such as sleep support, supplements, sports recovery, intimate care, or premium skincare may play a growth or margin role depending on the pharmacy’s clientele and positioning.
Once category roles are clear, decision-making becomes easier. Core categories should rarely be under-assorted, out of stock, or hard to find. Growth categories may justify more innovation and stronger visual presentation. Convenience or support categories can remain narrower if they are present mainly to complete the patient journey.
This approach also prevents a common mistake: expanding because a category feels fashionable rather than because it fits the store’s demand profile.
Use local demand, not generic market logic
National trends are useful, but local demand should carry more weight. A pharmacy near pediatric clinics, commuter zones, tourist areas, or an older population will not need the same assortment balance.
Review sales by category, SKU turnover, gross margin, seasonality, basket attachment, and recommendation frequency. Also look beyond sales reports. Ask staff which requests recur, which products require explanation, and which substitutions happen regularly because the expected option is missing.
Good assortment planning combines quantitative and qualitative inputs. Data shows what sold. Staff insight explains why customers asked, hesitated, switched, or left without buying.
There is also a timing issue. Pharmacies that plan only once a year are usually too slow. Seasonal categories, epidemiological shifts, and local market changes require periodic reassessment. That does not mean constant change on the shelf. It means managing the assortment with a calendar and intent.
Breadth and depth: where many pharmacies lose money
The key commercial tension in assortment planning is breadth versus depth. Breadth is how many different products or variants you carry. Depth is how much stock you hold within selected items.
Too much breadth confuses shoppers and fragments demand across similar SKUs. Too little breadth can make the pharmacy feel incomplete and force patients to shop elsewhere. The right balance depends on category behavior.
In high-need, faster-turning OTC categories, a tighter range with stronger stock depth often performs better than a crowded shelf. In advisory categories where customer preferences vary more, a somewhat broader selection can support choice and pharmacist recommendation.
The same logic applies to brand architecture. Carrying three leading brands plus one value option may be enough in a category where therapeutic purpose is clear. Carrying seven brands with overlapping claims usually does not improve the business. It often weakens it.
Managers should be willing to delist slow, redundant, or low-identity SKUs even when they are not complete failures. The real question is opportunity cost. What could that shelf space and working capital do elsewhere?
Shelf productivity should guide the final decision
A product does not earn its place because it exists in the wholesaler catalog. It earns its place by contributing to sales, gross profit, patient relevance, strategic image, or a combination of these.
That means assortment planning should be tied to shelf productivity. Evaluate sales per facing, gross profit per linear foot, and how visible placement aligns with category priority. Some categories deserve eye-level prominence. Others can remain present with less space if they are destination purchases or low-advice commodities.
Planograms matter here, but they should come after strategic decisions, not replace them. A tidy shelf cannot compensate for a weak assortment logic.
It is also important to separate assortment from inventory excess. A good assortment can still be undermined by poor replenishment settings. If core products are repeatedly out of stock while tertiary variants remain overbought, the issue is not only range design. It is stock discipline.
Supplier relationships help – if the pharmacy keeps control
Supplier input can be valuable, especially in identifying innovation, consumer trends, and category education needs. But assortment ownership must remain with the pharmacy.
The risk is allowing vendor proposals to shape the shelf one meeting at a time. Over several months, this creates fragmented category architecture and brand-heavy displays without a clear business rationale. Pharmacies should evaluate every proposed addition against category role, store positioning, expected turnover, and cannibalization risk.
A useful rule is simple: every new SKU should replace weak productivity or create clearly incremental value. If it does neither, it probably does not belong.
The team must be able to sell the assortment
An assortment is only as effective as the staff’s confidence in recommending it. If there are too many similar options, the team either defaults to familiar products or avoids active recommendation altogether. Both outcomes limit category performance.
A cleaner, better-structured assortment improves not only customer navigation but also staff communication. Pharmacists and assistants can explain differences more clearly, guide choices faster, and support add-on sales more naturally when the shelf has logic.
This is especially relevant in self-care categories where trust and advice remain competitive advantages for pharmacy versus mass retail and online channels.
A practical standard for better non prescription assortment planning
For most pharmacies, improvement does not require a complete reset. It requires a disciplined review of the categories that matter most. Start with the top OTC and front-of-store categories by revenue and margin. Define each category role, remove duplication, protect top sellers, test fewer but stronger options, and align space with contribution.
Then monitor what changes. Did stock turns improve? Did recommendation-based sales become easier? Did the category become simpler to shop? Did gross profit rise even if the SKU count fell? Those are the signals that planning is working.
Non prescription assortment planning is not about carrying less for its own sake. It is about carrying better. When the assortment matches local demand, category role, and pharmacy positioning, the shelf stops being passive storage and starts functioning as a commercial asset.
The pharmacies that improve front-of-store performance consistently are usually not the ones with the most products. They are the ones that know why each product is there.
